Biotech vet Gould lands $55M startup round for a new Third Rock platform biotech
After leaving the helm of Epizyme last fall, Robert Gould took some time off, then took some more time to look over some biotech startups …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
